EUVIMED · CrossrefZeitschrift
International Journal of Lung Cancer
ISSN 3117-504X · Elsevier BV
Neueste Artikel
Frequency and safety of pegfilgrastim use in patients with lung cancer treated with combination therapy of cytotoxic chemotherapy and immune checkpoint inhibitors: A CS-lung-003-registry-based prospective observational study
The changing landscape of stage IV lung squamous cell carcinoma: Long-term trends with immune checkpoint inhibitors and contemporary regimens
Difficulty in differentiating lymphoma arising in methotrexate-related immune deficiency/dysregulation from lung cancer: A case report
Competing mortality risks in radiologically aggressive stage IA1–2 non-small cell lung cancer
Survival after initial non-treatment of registry-identified early-stage lung cancer: outcomes in patients with interstitial lung disease
Prognostic nutritional index as a predictor of survival in stage IV lung cancer undergoing palliative radiation therapy
Launching the International Journal of Lung Cancer
Repotrectinib was effective for carcinomatous meningitis occurring during the treatment of early-generation ROS1 TKIs for ROS1 fusion-positive NSCLC: A case report
Health care resource utilization and cardiovascular outcomes in lung cancer patients receiving immunotherapy in relation to smoking status: A retrospective cohort study and systematic review
Model for predicting completion of chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer: Analysis of pooled data from a clinical trial database
Safety and efficacy of carboplatin-etoposide plus an immune checkpoint inhibitor and with primary prophylactic pegylated granulocyte colony-stimulating factor in patients with small cell lung cancer
Incidence of leptomeningeal metastasis and prognosis after its development in patients with advanced non-small cell lung cancer: a prospective real-world observational study (CS-Lung-003-linked study 37)
Thromboembolic events in non-small cell lung cancer patients treated with vascular endothelial growth factor inhibitors: A preliminary retrospective single-center study
Real-world evidence of postoperative adjuvant chemotherapy in patients with stage IA–IIIA non-small cell lung cancer in Japan
Autoimmune hemolytic anemia following ipilimumab plus nivolumab therapy in a patient with malignant pleural mesothelioma: A case report
Pulmonary combined large-cell neuroendocrine carcinoma with adenocarcinoma and pleomorphic carcinoma components: A case report
Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR-mutated non-small-cell lung cancer: a single-center retrospective cohort study
Long-term outcomes of neoadjuvant nivolumab plus chemotherapy in resectable NSCLC in Japanese patients: final 5-year follow-up analysis from CheckMate 816
Definitive diagnosis of pleural mesothelioma by pleural effusion cytology: the MesoCyto study
First-line taxane-versus pemetrexed-based chemoimmunotherapy for TTF-1–negative nonsquamous non–small cell lung cancer: a propensity score–matched study
Clinical utility of comprehensive genomic profiling in detecting actionable EGFR exon 20 insertions undetected by companion diagnostics: a case report
First-line pembrolizumab in metastatic non-small cell lung cancer: A clinical text-mining analysis of effectiveness, costs, and trial eligibility
A comparison of cisplatin plus S-1 versus mitomycin C, vindesine, and cisplatin in concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer: A target trial emulation study using a clinical trial database
Real-world clinical outcomes of immune checkpoint inhibitors beyond 2 Years in patients with non-small cell lung cancer: A multicenter retrospective study
Ixazomib enhances the antitumor effect of brigatinib in TP53-mutated EML4-ALK lung cancer cells
Real-world comparison of carboplatin–pemetrexed–bevacizumab versus chemo-immunotherapy in EGFR-mutated lung cancer
Effect of prior chemotherapy on survival in patients from the randomized phase III J-ALEX study of alectinib versus crizotinib in ALK-positive non-small cell lung cancer
A multicenter, randomized phase III trial comparing osimertinib with durvalumab after concurrent chemoradiotherapy in patients with unresectable, locally advanced non–small cell lung cancer harboring EGFR mutations: JCOG2502 (ODYSSEIA)
Tumor size assessment for prediction of osimertinib efficacy in EGFR-mutated non–small cell lung cancer
Safety and effectiveness of capmatinib in patients with unresectable advanced/recurrent non-small cell lung cancer with METex14 skipping alterations: a post-marketing surveillance in Japan
EUVIMED